Safety and efficacy of growth hormone replacement therapy in adults

Andrew Toogood

Research output: Contribution to journalReview article

7 Citations (Scopus)


Limitless supplies of recombinant human growth hormone (GH) have been available for the last 20 years. During that period, studies have characterised the effects of GH deficiency in adults and the benefits of GH replacement therapy. Areas of greatest impairment and benefit are quality of life, skeletal health and cardiovascular risk factors including the serum lipid profile and body composition. By optimising GH replacement therapy at various stages of adult life, it is hoped that it will prevent the development of osteoporosis and reduce the mortality and morbidity associated with hypopituitarism. However, the primary indication for GH therapy in adults in England and Wales is quality of life. The benefits of GH treatment are sustained over several years, and long-term surveillance of patients continues.
Original languageEnglish
Pages (from-to)1069-1082
Number of pages14
JournalExpert Opinion on Drug Safety
Publication statusPublished - 1 Nov 2005


Dive into the research topics of 'Safety and efficacy of growth hormone replacement therapy in adults'. Together they form a unique fingerprint.

Cite this